Argenx buoyed by PhII trial results; Boehringer touts a big batch of real-world COPD data

→ Shares of Belgium’s argenx $ARGX edged up this morning as the company touted top-line data from its Phase II study of efgartigimod (ARGX-113) in adult primary immune thrombocytopenia patients. Researchers said that the drug spurred “clinically meaningful platelet count improvements across doses and ITP patient classifications, including newly diagnosed, persistent and chronic, and correlated with a consistent reduction in IgG levels.”

Boehringer Ingelheim underscored the growing importance of real-world data today with its results from the OTIVACTO study, an observational study involving 7,443 COPD patients treated with Spiolto Respimat (tiotropium/olodaterol). “Patients in the study reported both improved physical functioning and general condition and high satisfaction with their inhalation device and treatment overall. The improvements were observed in patients across disease severities,” the company noted.

→ Lexington, MA-based Agenus $AGEN picked up a $5 million milestone from Incyte on the start of a Phase I clinical trial of INCAGN2385, their anti-LAG-3 antibody.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->